Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

N. Justice, Jamie; M. Nambiar, Anoop; Tchkonia, Tamar; K. LeBrasseur, Nathan; M. Pascual, Rodolfo; Hashmi, Shahrukh; Prata, Larissa; M. Masternak, Michał; B. Kritchevsky, Stephen; Musi, Nicolas; L. Kirkland, James

doi:10.1016/j.ebiom.2018.12.052

Public

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study

Published in EBioMedicine • Jan 4, 2019

Authors:

Jamie N. Justice

Anoop M. Nambiar

Tamar Tchkonia

Abstract

BACKGROUND: Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus que...

Subject

Medicine

Idiopathic pulmonary fibrosis

Pulmonary fibrosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!